Literature DB >> 1394149

Non-Hodgkin's lymphoma time trends: United States and international data.

S S Devesa1, T Fears.   

Abstract

Incidence data from the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute, earlier incidence surveys, and the International Agency for Research on Cancer, mortality data from the National Center for Health Statistics, and population data from the Census Bureau were used to assess rates of non-Hodgkin's lymphoma. Mortality and incidence rates have been increasing for many years. Larger increases among older persons suggest a role for improving diagnosis, particularly during the 1950s and 1960s. Urban/rural and socioeconomic differences have diminished over time. Since the early 1970s, incidence rates increased at 3-4%/year, more rapidly than for all other cancers except melanoma of the skin and lung cancer among women. Incidence rates increased over all ages except the very young, among whites and blacks, in geographic areas both in the United States and internationally, and both sexes. During the 1980s, the impact of AIDS is apparent among young and middle-aged men. Differences in non-Hodgkin's lymphoma rates persist between races and sexes. Increases have been more marked for extranodal disease, particularly those arising in the brain, and for high-grade tumors. Explanations accounting for all the increases in rates are not readily available.

Entities:  

Mesh:

Year:  1992        PMID: 1394149

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  57 in total

1.  Primary intestinal non-Hodgkin's lymphoma: a clinicopathologic analysis of 81 patients.

Authors:  Guo-Bao Wang; Guo-Liang Xu; Guang-Yu Luo; Hong-Bo Shan; Yin Li; Xiao-Yan Gao; Jian-Jun Li; Rong Zhang
Journal:  World J Gastroenterol       Date:  2011-11-07       Impact factor: 5.742

Review 2.  Vaccination strategies for lymphomas.

Authors:  Mohammed M Dar; Larry W Kwak
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

3.  Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy.

Authors:  Scott F Huntington; Mahsa S Talbott; John P Greer; David S Morgan; Nishitha Reddy
Journal:  Leuk Lymphoma       Date:  2012-03-01

4.  Non-Hodgkin lymphoma in early life.

Authors:  Benjamin Emmanuel; William F Anderson
Journal:  J Natl Cancer Inst       Date:  2012-05-22       Impact factor: 13.506

5.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

Authors:  Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

Review 6.  PET in lymphoma.

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2006-10-31       Impact factor: 3.909

7.  Epidemiology of non-Hodgkin lymphomas in Tyrol/Austria from 1991 to 2000.

Authors:  T Mitterlechner; M Fiegl; H Mühlböck; W Oberaigner; S Dirnhofer; A Tzankov
Journal:  J Clin Pathol       Date:  2006-01       Impact factor: 3.411

8.  Case report: a patient with primary CNS lymphoma treated with temozolomide to complete response.

Authors:  Keith A Lerro; Jill Lacy
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

9.  Features of primary extranodal lymphoma in Kanagawa, a human T-cell leukemia virus type 1 nonendemic area in Japan.

Authors:  Atsuko Fujita; Naoto Tomita; Hiroyuki Fujita; Kenji Motohashi; Rie Hyo; Etsuko Yamazaki; Michiko Hattori; Shin Fujisawa; Heiwa Kanamori; Koji Ogawa; Shigeki Motomura; Fumio Kodama; Yoshiaki Ishigatsubo
Journal:  Med Oncol       Date:  2008-06-21       Impact factor: 3.064

10.  Solvent exposure and non-Hodgkin lymphoma: no risk in a population-based study in the San Francisco Bay Area.

Authors:  Gregory J Tranah; Elizabeth A Holly; Paige M Bracci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-11       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.